menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC

ReachMD Healthcare Image
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    A recent study investigated the efficacy of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable non-small cell lung cancer (NSCLC). Learn more about the results from the AGEAN trial with this brief recap. 

Facebook Comments

Recommended
Details
Comments
  • Overview

    A recent study investigated the efficacy of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable non-small cell lung cancer (NSCLC). Learn more about the results from the AGEAN trial with this brief recap. 

Facebook Comments

Schedule27 May 2024